A Phase 2 Study of Denosumab for Prevention of Skeletal Disease Progression in Children With Fibrous Dysplasia
Latest Information Update: 23 Jan 2026
At a glance
- Drugs Denosumab (Primary)
- Indications Bone disorders; Fibrous dysplasia of bone
- Focus Therapeutic Use
Most Recent Events
- 20 Jan 2026 Actual Primary Completion Date is 9 Jan 2026.
- 20 Jan 2026 Status changed from active, no longer recruiting to completed.
- 29 Jan 2025 Status changed from recruiting to active, no longer recruiting.